内容

目次

Section 1: Lung Cancer Control and Epidemiology 1. Classical Epidemiology 2. Tobacco Control and Primary Prevention 3. Tobacco Cessation 4. Non-Smoking Related Lung Cancer 5. Gender-Related Differences in Lung Cancer 6. Genetic Susceptibility to Lung Cancer 7. Early Detection and Radiologic Screening 8. Preclinical Biomarkers for The Early Detection of Lung Cancer 9. Chemoprevention of Lung Cancer: Present and Developing Technologies Section 2: Lung Cancer Molecular Carcinogenesis 10. Copy Number Abnormalities and Gene Rearrangements in Lung Cancer: Present and Developing Technologies 11. Mutational Events in Lung Cancer: Present and Developing Technologies 12. Epigenetic Events, Alterations, and Remodeling in Lung Cancer: Present and Developing Technologies 13. Stem Cells and Lung Cancer: In Vitro and In Vivo Studies 14. Microenvironment and Lung Cancer 15. MicroRNAs as Biomarkers for Lung Cancer Section 3: Immunology 16. Humoral and Cellular Immune Dysregulation and Lung Cancer Section 4: Pathology 17. Classic Anatomic Pathology and Lung Cancer 18. Molecular Testing and Lung Cancer 19. Management of the Small Biopsy in the Molecular Er Section 5: Clinical and Radiologic Presentation of Lung Cancer 20. Clinical Presentation 21. Conventional Imaging Lung Cancer 22. PET Imaging of Lung Cancer Section 6: Diagnosis and Staging of Lung Cancer 23. Diagnostic Work-Up of Suspected Lung Cancer 24. Surgical Staging of the Mediastinum including Mediastinoscopy and Thoracoscopy, Preoperative and Intraoperative 25. The 8th Edition of the Tumor, Node and Metastasis Classification of Lung Cancer Section 7: Surgical Management of Lung Cancer 26. Preoperative Functional Evaluation of the Surgical Candidate 27. Results of Video Assisted Techniques for Resection of Lung Cancer 28. Results of Robotic Techniques for Resection of Lung Cancer 29. Extent of Surgical Resection for Stage I and II Lung Cancer 30. Extended Resections for Lung Cancer: Chest Wall and Pancoast Tumors 31. Extended Resections for Lung Cancer: Broncho/Vascular Sleeve Resections 32. Multiple Nodules: Management of the Patient with Synchronous or Metachronous Lung Cancers 33. Surgical Management of the Marginally Resectable Patient Section 8: Radiotherapeutic Management of Lung Cancer 34. Technical Requirements for Lung Cancer Radiotherapy 35. Radiobiology of Lung Cancer 36. Patient Selection for Radiotherapy 37. Stage I Non-Small Cell Lung Cancer and Oligometastatic Disease 38. Ablation Options for Localized Lung Cancer 39. Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer, including Combined Modality 40. Radiotherapy in the Management of Small Cell Lung Cancer: Thoracic Radiotherapy, Prophylactic Cranial Irradiation 41. Palliative Radiotherapy for Lung Cancer: Locoregional and Metastatic 42. Acute and Late Toxicities of Thoracic Radiotherapy: Pulmonary, Esophagus, Heart 43. Treatment-Related Neurotoxicity, Medical and Radiation Therapy Section 9: Chemotherapy and Targeted Agents for Lung Cancer 44. Front-Line Systemic Options in Non-Small Cell Lung Cancer 45. Systemic Options in Second Line and Beyond 46. Maintenance Therapy in NSCLC 47. Pharmacogenomics and Lung Cancer 48. New Targetable Pathways in Lung Cancer 49. Management of Toxicities of Targeted Therapies 50. Immunotherapy and Lung Cancer 51. Systemic Therapy in Early-Stage NSCLC 52. Treatment of Small-Cell Lung Cancer Section 10: Other Thoracic Malignancies 53. Malignant Mesothelioma 54. Mediastinal Tumors 55. Neuroendocrine Tumors of the Lung Other than SCLC 56. Thymic Cancer/Thymoma Section 11: Symptom Management and Complications 57. Lung Cancer Emergencies 58. Role of Palliative Care in Lung Cancer Section 12: Clinical Trials 59. Methodology of Clinical Trials in Lung Cancer 60. How to Promote and Organize Clinical Research in Lung Cancer Section 13: Thoracic Oncology Advocacy 61. Role of Advocacy Groups in Lung Cancer 62. Health Services Research in Lung Cancer Appendix 63. Appendix: Diagnostic Algorithms